2,438 results on '"Leiter, Lawrence A."'
Search Results
52. Weight management using meal replacements and cardiometabolic risk reduction in individuals with pre‐diabetes and features of metabolic syndrome: A systematic review and meta‐analysis of randomized controlled trials.
53. Correction to: The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus
54. Does empagliflozin modulate the autonomic nervous system among individuals with type 2 diabetes and coronary artery disease? The EMPA-HEART CardioLink-6 Holter analysis
55. Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials
56. Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial
57. Hypertension Canada’s 2020 Comprehensive Guidelines for the Prevention, Diagnosis, Risk Assessment, and Treatment of Hypertension in Adults and Children
58. Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials
59. The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial
60. Incidence of Myocardial Infarction Types in Patients Treated With Ticagrelor in the THEMIS Trial
61. Effects of albiglutide on myocardial infarction and ischaemic heart disease outcomes in patients with type 2 diabetes and cardiovascular disease in the Harmony Outcomes trial
62. Natriuretic Peptides, Body Mass Index and Heart Failure Risk: Pooled Analyses of SAVOR‐TIMI 53, DECLARE‐TIMI 58 and CAMELLIA‐TIMI 61
63. From glucose lowering agents to disease/diabetes modifying drugs: a “SIMPLE” approach for the treatment of type 2 diabetes
64. Latest Evidence on Sulfonylureas: What’s New?
65. Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada
66. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
67. Glycated Hemoglobin Level Goal Achievement in Adults With Type 2 Diabetes in Canada: Still Room for Improvement
68. Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management
69. Response to the Letter on “The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus”
70. Natriuretic peptides, body mass index and heart failure risk: Pooled analyses of SAVOR‐TIMI 53, DECLARE‐TIMI 58 and CAMELLIA‐TIMI 61.
71. Fructose-containing food sources and blood pressure: A systematic review and meta-analysis of controlled feeding trials
72. CardioDiabetes: Core Competencies for Cardiovascular Clinicians in a Rapidly Evolving Era of Type 2 Diabetes Management
73. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study
74. The place of gliclazide MR in the evolving type 2 diabetes landscape: A comparison with other sulfonylureas and newer oral antihyperglycemic agents
75. Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes
76. Hypertension Canada’s 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children
77. Blood Pressure Management in Adults With Type 2 Diabetes: Insights From the Diabetes Mellitus Status in Canada (DM-SCAN) Survey
78. Dyslipidemia
79. Treatment of Hypertension
80. Metabolic Surgery: Weight Loss, Diabetes, and Beyond
81. Insights Into the Current Management of Older Adults With Type 2 Diabetes in the Ontario Primary Care Setting
82. Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association
83. Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis
84. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
85. CANTOS Ushers in a New Calculus of Inflammasome Targeting for Vascular Protection—and Maybe More
86. P22-010-23 Coronary Heart Effectiveness Assessment of the Portfolio Diet in Primary Care (CHEAP) Trial: Protocol for a Randomized Controlled Trial
87. P24-046-23 Substitution of Sweetened Soymilk for Unsweetened Cow's Milk and Cardiometabolic Health: A Systematic Review and Meta-Analysis of Randomized Controlled Feeding Trials
88. Efficacy and safety of inclisiran in patients with cerebrovascular disease: ORION-9, ORION-10, and ORION-11
89. Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes
90. Abstract 16427: Efficacy and Safety of Inclisiran According to Age: A Pooled Analysis of Phase III Studies (ORION 9, 10 and 11)
91. Abstract 16311: Efficacy and Safety of Inclisiran According to Sex: A Pooled Analysis of the ORION 9, 10 and 11 Trials
92. Abstract 16139: A Targeted Proteomic Approach to Identify Circulating Biomarkers of Heart Failure Risk in Patients With Type 2 Diabetes Mellitus in DECLARE-TIMI 58
93. Abstract 15701: Relationship Between Cardiac Biomarkers and Major Adverse Cardiovascular Events in DECLARE-TIMI 58
94. Abstract 14961: External Applicability of REDUCE-IT in a Large Diabetes Cardiovascular Outcomes Trial: A Post Hoc Analysis of EMPA-REG OUTCOME
95. Abstract 14799: Cardiovascular Risk Stratification and Efficacy of Dapagliflozin on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the DECLARE-TIMI 58 Trial
96. Abstract 14248: Efficacy and Safety of Bempedoic Acid in Patients Who Cannot Tolerate Statins: Pooled Analysis of 4 Phase 3 Clinical Trials
97. Abstract 13814: Semaglutide Reduces Mace Consistently Across Baseline Triglyceride Levels in Patients With Type 2 Diabetes: A Post Hoc Analysis of the Sustain 6 and Pioneer 6 Trials
98. Abstract 13130: Efficacy and Safety of Bempedoic Acid by Sex: Pooled Analyses From Phase 3 Trials
99. Abstract 12923: Development of a Novel Biomarker-based Risk Score for Heart Failure in Patients With Diabetes
100. Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.